

18 June 2025

Receipt of Certificate of GMP Compliance with Europe, Canada, Singapore, and United Kingdom

Bioxyne Limited (ASX: BXN) (Bioxyne or Company), through its wholly owned subsidiary Breathe Life Sciences (BLS), has received certificates of GMP compliance under Mutual Recognition Agreements with countries including:

1. Australia – the manufacturer complies with the GMP requirements of the PIC/S Guide to Good Manufacturing Practice for Medicinal Products – 01 May 2021;
2. Singapore – the manufacturer complies with the GMP requirements of the Agreement of Mutual Recognition between Australia and Singapore;
3. Euro Zone – the manufacturer complies with the GMP requirements of the Agreement of Mutual Recognition between Australia and The European Free Trade Association;
4. European Union – the manufacturer complies with the GMP requirements of the Agreement of Mutual Recognition between Australia and The European Community;
5. Canada – the manufacturer complies with the GMP requirements of the Agreement of Mutual Recognition between Australia and Canada;
6. United Kingdom – the manufacturer complies with the GMP requirements of the Agreement of Mutual Recognition between Australia and The United Kingdom of Great Britain and Northern Ireland.

The Company is pleased to gain certification as it moves to expand its presence globally, with particular emphasis on European markets and the United Kingdom.

Positive Outlook for FY2026

Bioxyne is positioned for continued growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries.

The Company expects to deliver guidance for FY2026 in August.

This announcement has been approved by the Board for lodgement with the ASX.



About Bioxyne Limited:

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative medicines and active pharmaceutical ingredients.

For further information, please contact:

Bioxyne Limited
Investor Relations
Email: info@bioxyne.com
Phone: +61 2 9078 8180
Website: www.bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.

- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbn.com
 - **UK / EU:** breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

